<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01439854</url>
  </required_header>
  <id_info>
    <org_study_id>5 R01 DK024092-27/NIH Prot IV</org_study_id>
    <secondary_id>R01DK024092</secondary_id>
    <nct_id>NCT01439854</nct_id>
  </id_info>
  <brief_title>Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action</brief_title>
  <acronym>DAPA MITO</acronym>
  <official_title>Regulation of Hepatic and Peripheral Glucose Metabolism: Protocol IVA. Effect of Plasma Glucose Reduction by Selective SLGT2 Inhibition on Mitochondrial Dysfunction and Impaired Insulin Signaling/Sensitivity in T2DM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effect of the chronic treatment of type 2
      diabetes (T2DM) with dapagliflozin on: (1) mitochondrial gene function/expression and insulin
      signaling/action and (2) oral glucose tolerance and beta cell function. Dapagliflozin is a
      potent, highly specific inhibitor of renal glucose transport [SGLT2].
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      &quot;Glucotoxicity&quot; has been implicated as a cause of insulin resistance and impaired beta cell
      function in T2DM. Abundant support for the glucotoxicity hypothesis has been provided by in
      vivo and in vitro studies in animals, but a rigorous test of this hypothesis in man is
      lacking. The investigators propose to test the glucotoxicity hypothesis by chronically
      reducing the plasma glucose in type 2 diabetic subjects (T2DM) with an inhibitor of renal
      glucose transport, dapaglifozin, and examining the effect of restoration of normoglycemia on
      mitochondrial function and insulin signaling/sensitivity. Lastly, the investigators will test
      the &quot;glucolipotoxicity&quot; hypothesis, which states that the toxic effects of elevated plasma
      FFA on insulin sensitive tissues (i.e., muscle) are magnified in the presence of concurrent
      hyperglycemia. Thus, high glucose levels increase malonyl CoA, which inhibits CPT I, leading
      to accumulation of FACoA/DAG, which impair mitochondrial function and inhibit insulin action.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">June 30, 2018</completion_date>
  <primary_completion_date type="Actual">June 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Insulin Sensitivity</measure>
    <time_frame>baseline, two weeks</time_frame>
    <description>The change in insulin sensitivity and total glucose disposal measured at two weeks with the insulin clamp compared to baseline. This is measured using TGD (whole body tissue glucose disposal)/SSPI (steady state plasma insulin concentration) ratio</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Mitochondrial Function</measure>
    <time_frame>baseline, two weeks</time_frame>
    <description>The change in mitochondrial function/gene expression at two weeks compared to baseline. This was measured by energy expenditure.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Insulin Sensitivity</condition>
  <condition>Multiple Mitochondrial Dysfunctions Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>this arm is control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interventional arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>Treatment arm, 10 mg per day for 2 weeks</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients are treated with placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  T2DM

          -  Drug Naive Or On Oral Therapy

        Exclusion Criteria:

          -  Insulin Treatment

          -  Major Organ Disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralph DeFronzo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center at San Antonio</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Devjit Tripathy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center at San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diabetes Division, UTHSCSA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://care.diabetesjournals.org/content/39/11/2036</url>
    <description>ADA Diabetes Care 2016 Nov; 39(11): 2036-2041</description>
  </link>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>August 3, 2011</study_first_submitted>
  <study_first_submitted_qc>September 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2011</study_first_posted>
  <results_first_submitted>September 16, 2019</results_first_submitted>
  <results_first_submitted_qc>October 10, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 29, 2019</results_first_posted>
  <last_update_submitted>October 10, 2019</last_update_submitted>
  <last_update_submitted_qc>October 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Insulin sensitivity</keyword>
  <keyword>Mitochondrial function</keyword>
  <keyword>Glucose toxicity</keyword>
  <keyword>Glucosuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 10, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT01439854/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>this arm is control
Placebo: Patients are treated with placebo</description>
        </group>
        <group group_id="P2">
          <title>Dapagliflozin</title>
          <description>Interventional arm
Dapagliflozin: Treatment arm, 10 mg per day for 2 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>this arm is control
Placebo: Patients are treated with placebo</description>
        </group>
        <group group_id="B2">
          <title>Dapagliflozin</title>
          <description>Interventional arm
Dapagliflozin: Treatment arm, 10 mg per day for 2 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.4" spread="2.1"/>
                    <measurement group_id="B2" value="51.9" spread="2.3"/>
                    <measurement group_id="B3" value="53.6" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.6" spread="1.5"/>
                    <measurement group_id="B2" value="30.9" spread="1.8"/>
                    <measurement group_id="B3" value="31.8" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>A1C (average blood glucose level over 3 months</title>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.7" spread="0.4"/>
                    <measurement group_id="B2" value="8.5" spread="0.4"/>
                    <measurement group_id="B3" value="8.6" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Insulin Sensitivity</title>
        <description>The change in insulin sensitivity and total glucose disposal measured at two weeks with the insulin clamp compared to baseline. This is measured using TGD (whole body tissue glucose disposal)/SSPI (steady state plasma insulin concentration) ratio</description>
        <time_frame>baseline, two weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>this arm is control
Placebo: Patients are treated with placebo</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin</title>
            <description>Interventional arm
Dapagliflozin: Treatment arm, 10 mg per day for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin Sensitivity</title>
          <description>The change in insulin sensitivity and total glucose disposal measured at two weeks with the insulin clamp compared to baseline. This is measured using TGD (whole body tissue glucose disposal)/SSPI (steady state plasma insulin concentration) ratio</description>
          <units>mg/kg.min per ÂµU/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Measurement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.18" spread="0.51"/>
                    <measurement group_id="O2" value="3.85" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.57" spread="0.51"/>
                    <measurement group_id="O2" value="5.22" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mitochondrial Function</title>
        <description>The change in mitochondrial function/gene expression at two weeks compared to baseline. This was measured by energy expenditure.</description>
        <time_frame>baseline, two weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>this arm is control
Placebo: Patients are treated with placebo</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin</title>
            <description>Interventional arm
Dapagliflozin: Treatment arm, 10 mg per day for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mitochondrial Function</title>
          <description>The change in mitochondrial function/gene expression at two weeks compared to baseline. This was measured by energy expenditure.</description>
          <units>cal/min.kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Measurement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" spread="0.1"/>
                    <measurement group_id="O2" value="1.3" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Measurement at 2 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.1"/>
                    <measurement group_id="O2" value="1.34" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events are collected over a 2 week period</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>this arm is control
Placebo: Patients are treated with placebo</description>
        </group>
        <group group_id="E2">
          <title>Dapagliflozin</title>
          <description>Interventional arm
Dapagliflozin: Treatment arm, 10 mg per day for 2 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Muhammad Abdul-Ghani</name_or_title>
      <organization>University of Texas Health San Antonio</organization>
      <phone>210-557-1157</phone>
      <email>abdulghani@uthscsa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

